EyeGate lands $15M in third round

With the help of Medicis Capital, Ventech, Innoven Partenaires and The Nexus Group, Eyegate has landed $15 million in a third round of venture funding. According to EyeGate President and CEO Stephen From, the company will use the funding to commence two Phase II clinical studies using the EyeGate II Delivery System and it's own formulation of a corticosteroid. Eyegate will study the drug for severe uveitis in the first half of 2008, and a second trial for dry eye will start later this year. To date, the company has raised  $31 million in funding.

- here's the release for more

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.